HbA(1c) as a screening tool for detection of Type 2 diabetes: a systematic review.

Diabet Med. 2007 Apr;24(4):333-43. Epub 2007 Mar 15. Click here to read LinkOut

Erratum in:
Diabet Med. 2007 Sep;24(9):1054.
Comment in:
Evid Based Med. 2007 Oct;12(5):152.

Bennett CM, Guo M , Dharmage SC .

Department of Public Health, School of Population Health, The University of Melbourne, Australia. c.bennett@unimelb.edu.au

AIM: To assess the validity of glycated haemoglobin A(1c) (HbA(1c)) as a screening tool for early detection of Type 2 diabetes. METHODS: Systematic review of primary cross-sectional studies of the accuracy of HbA(1c) for the detection of Type 2 diabetes using the oral glucose tolerance test as the reference standard and fasting plasma glucose as a comparison. RESULTS Nine studies met the inclusion criteria. At certain cut-off points, HbA(1c) has slightly lower sensitivity than fasting plasma glucose (FPG) in detecting diabetes, but slightly higher specificity. For HbA(1c) at a Diabetes Control and Complications Trial and UK Prospective Diabetes Study comparable cut-off point of > or = 6.1%, the sensitivity ranged from 78 to 81% and specificity 79 to 84%. For FPG at a cut-off point of > or = 6.1 mmol/l, the sensitivity ranged from 48 to 64% and specificity from 94 to 98%. Both HbA(1c) and FPG have low sensitivity for the detection of impaired glucose tolerance (around 50%). CONCLUSIONS HbA(1c) and FPG are equally effective screening tools for the detection of Type 2 diabetes. The HbA(1c) cut-off point of > 6.1% was the recommended optimum cut-off point for HbA(1c) in most reviewed studies; however, there is an argument for population-specific cut-off points as optimum cut-offs vary by ethnic group, age, gender and population prevalence of diabetes. Previous studies have demonstrated that HbA(1c) has less intra-individual variation and better predicts both micro- and macrovascular complications. Although the current cost of HbA(1c) is higher than FPG, the additional benefits in predicting costly preventable clinical complications may make this a cost-effective choice.

PMID: 17367307 [PubMed – indexed for MEDLINE]

Related Links

See all Related Articles…

 Display SummaryBriefAbstractAbstractPlusCitation MEDLINEXMLUI ListLinkOutASN.1Related Articles Cited in BooksCancerChrom LinksDomain Links3D Domain Links GEO DataSet LinksGene LinksGene (GeneRIF) LinksGenome Links Project LinksGENSAT LinksGEO Profile LinksHomoloGene LinksCoreNucleotide Links CoreNucleotide (RefSeq) LinksEST LinksEST (RefSeq) Links GSS LinksGSS (RefSeq) LinksNucleotide LinksNucleotide (RefSeq) Links OMIA LinksOMIM (calculated) LinksOMIM (cited) LinksBioAssay Links Compound LinksCompound (MeSH Keyword)Compound (Publisher) LinksSubstance Links Substance (MeSH Keyword)Substance (Publisher) LinksPMC Links Cited in PMCPopSet LinksProbe LinksProtein LinksProtein (RefSeq) Links Protein Cluster LinksCited ArticlesSNP LinksStructure Links Taxonomy via GenBankUniGene LinksUniSTS Links Show 5102050100200500 Sort ByPub Date First AuthorLast AuthorJournal Send toTextFilePrinterClipboardE-mail Order

2 thoughts on “HbA(1c) as a screening tool for detection of Type 2 diabetes: a systematic review.”

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s